Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1979 Jun;7(6):623–624. doi: 10.1111/j.1365-2125.1979.tb04653.x

When can 'non significantly different' treatments be considered as 'equivalent'?

A Spriet, D Beiler
PMCID: PMC1429671  PMID: 465284

Full text

PDF
623

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Calimlim J. F., Wardell W. M., Lasagna L., Gillies A. J., Davis H. T. Effect of naloxone on the analgesic activity of methadone in a 1:10 oral combination. Time and cost of flirting with the null hypothesis in tests of equivalence. Clin Pharmacol Ther. 1974 Jun;15(6):556–564. doi: 10.1002/cpt1974156556. [DOI] [PubMed] [Google Scholar]
  2. Chaput de Saintonge D. M., Vere D. W., Sharman V. L. Diazepam or nitrazepam? A question of cost. Br J Clin Pharmacol. 1977 Aug;4(4):492–494. doi: 10.1111/j.1365-2125.1977.tb00772.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Derogatis L. R., Bonato R. R., Yang K. C. The power of IMPS in psychiatric drug research: as a function of sample size, number of raters, and choice of treatment comparison. Arch Gen Psychiatry. 1968 Dec;19(6):689–699. doi: 10.1001/archpsyc.1968.01740120049008. [DOI] [PubMed] [Google Scholar]
  4. Dunnett C. W., Gent M. Significance testing to establish equivalence between treatments, with special reference to data in the form of 2X2 tables. Biometrics. 1977 Dec;33(4):593–602. [PubMed] [Google Scholar]
  5. Feinstein A. R. Clinical biostatistics. XXXIV. The other side of 'statistical significance': alpha, beta, delta, and the calculation of sample size. Clin Pharmacol Ther. 1975 Oct;18(4):491–505. doi: 10.1002/cpt1975184491. [DOI] [PubMed] [Google Scholar]
  6. Matthysse S. Concept of 'significance' misunderstood. Arch Gen Psychiatry. 1978 Jul;35(7):904–904. doi: 10.1001/archpsyc.1978.01770310110010. [DOI] [PubMed] [Google Scholar]
  7. Overall J. E., Hollister L. E., Dalal S. N. Psychiatric drug research. Sample size requirements for one vs two raters. Arch Gen Psychiatry. 1967 Feb;16(2):152–161. doi: 10.1001/archpsyc.1967.01730200020004. [DOI] [PubMed] [Google Scholar]
  8. Sackett D. L., Spitzer W. O., Gent M., Roberts R. S. The Burlington randomized trial of the nurse practitioner: health outcomes of patients. Ann Intern Med. 1974 Feb;80(2):137–142. doi: 10.7326/0003-4819-80-2-137. [DOI] [PubMed] [Google Scholar]
  9. Strickland I. D., Chaput de Saintonge D. M., Boulton F. E., Francis B., Roubikova J., Waters J. I. The therapeutic equivalence of oral and intravenous iron in renal dialysis patients. Clin Nephrol. 1977 Feb;7(2):55–57. [PubMed] [Google Scholar]
  10. Wade O. L., Waterhouse J. A. Significant or important? Br J Clin Pharmacol. 1977 Aug;4(4):411–412. doi: 10.1111/j.1365-2125.1977.tb00755.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Westlake W. J. Symmetrical confidence intervals for bioequivalence trials. Biometrics. 1976 Dec;32(4):741–744. [PubMed] [Google Scholar]
  12. Wulff H. R. Letter: Confidence limits in evaluating controlled therapeutic trials. Lancet. 1973 Oct 27;2(7835):969–970. doi: 10.1016/s0140-6736(73)92631-7. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES